Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
1. The number and function of circulating endothelial progenitor cells (EPCs) are inversely
associated with coronary risk factors and atherosclerotic diseases such as PAOD.
2. This double-blind, randomized, placebo-controlled trial to evaluate the effects of
cilostazol on human early EPCs and angiogenesis as well as the potential mechanisms of
action in patients with mild-to-moderate PAOD.
Phase:
Phase 4
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborator:
Department of Health, Executive Yuan, R.O.C. (Taiwan)